Mupirocin Topical

Introduction Overview

Generic Name

mupirocin topical

Brand Name

Bactroban

Dosage Form

Topical cream, ointment, and nasal ointment

Drug Class

Topical antibiotics

Pharmacokinetics

Absorption

When applied topically, mupirocin exhibits minimal systemic absorption through intact skin, with less than 1% of the applied dose detectable in plasma, making systemic exposure negligible. However, absorption may be increased if applied to large skin areas, broken or denuded skin, or with occlusive dressings. Due to minimal systemic absorption, oral bioavailability is not clinically relevant as mupirocin is not administered systemically.

Distribution

Following topical application, systemic distribution is minimal owing to the limited absorption through the skin. When absorption occurs, mupirocin binds moderately to plasma proteins, although plasma concentrations remain very low. The drug primarily remains localized at the site of application, exerting its antimicrobial effect locally without significant systemic distribution.

Metabolism

Mupirocin is metabolized rapidly at the site of application to its inactive derivative, monic acid, via hydrolysis of the mupirocin molecule. This metabolic conversion occurs primarily in the skin and mucous membranes. Systemically absorbed mupirocin is further metabolized in the liver to inactive metabolites. The metabolic pathways reduce the potential for systemic toxicity.

Elimination

Elimination of mupirocin and its metabolites occurs mainly via renal excretion following metabolism. Due to the minimal systemic absorption, urinary excretion of detectable mupirocin is low. The elimination half-life after topical administration has not been extensively characterized but is consistent with rapid metabolism and clearance. Unabsorbed drug remains at the site of application and is degraded or removed with skin turnover.

Dosage Forms

Adults

Bactroban topical is available as a cream and an ointment for cutaneous application, typically applied to affected skin areas three times daily for up to 10 days. For nasal carriage eradication, a specialized nasal ointment is applied inside each nostril three times daily for 5 days.

Adolescents

Dosing in adolescents mirrors adult recommendations. Topical cream or ointment should be applied three times daily to affected areas for up to 10 days; nasal ointment is dosed similarly for nasal decolonization over 5 days.

Special Populations

In pediatric patients, the ointment formulation can be used in children as young as 2 months, while the cream is not recommended for children under 3 months. Safety in pregnancy and lactation has not been established; use only if clearly needed. No dose adjustment is required in patients with renal impairment due to minimal systemic absorption. Limited data exist regarding hepatic impairment, but systemic exposure is low. Application should be limited to small areas to prevent potential systemic effects.

Mechanism Of Action

Mupirocin exerts its antibacterial effect by reversibly binding to bacterial isoleucyl-tRNA synthetase, an essential enzyme involved in protein synthesis. This binding inhibits the enzyme's activity, leading to the prevention of isoleucine incorporation into bacterial proteins, thereby halting bacterial protein synthesis at an early stage. This mechanism is bacteriostatic at low concentrations but bactericidal at higher concentrations against susceptible pathogens.

At the cellular level, mupirocin's inhibition of isoleucyl-tRNA synthetase disrupts the translation process, causing bacterial growth arrest and eventual death due to the inability to synthesize vital proteins. This targeted mechanism explains mupirocin's selective action on bacteria without affecting mammalian cells, as mammalian isoleucyl-tRNA synthetase has a different structure and affinity.

Clinically, this unique mechanism underlies mupirocin’s efficacy against Gram-positive bacteria, particularly Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Streptococcus pyogenes. Unlike beta-lactam antibiotics that target cell wall synthesis, mupirocin targets protein synthesis, making it effective against bacteria resistant to other antibiotic classes.

Research studies have demonstrated mupirocin's ability to eradicate nasal carriage of S. aureus and treat superficial skin infections such as impetigo by reducing bacterial load at the infection site. Its topical use helps prevent systemic side effects and limits resistance development compared to systemic antibiotics.

Pharmacological Actions

Inhibits bacterial protein synthesis by targeting bacterial isoleucyl-tRNA synthetase
Bacteriostatic at low concentrations and bactericidal at higher concentrations
Effective primarily against Gram-positive bacteria including Staphylococcus aureus and Streptococcus pyogenes
Topical antibacterial activity with limited systemic absorption
Reduces bacterial colonization on skin and mucous membranes
Demonstrates activity against methicillin-resistant Staphylococcus aureus (MRSA) strains
Prevents bacterial growth and proliferation in infected skin areas
Used for nasal decolonization of S. aureus carriers to reduce infection risk

Therapeutic Clinical Uses

Topical treatment of superficial skin infections such as impetigo
Treatment of secondary bacterial infections caused by susceptible organisms on skin wounds
Eradication of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) to prevent spread and infection
Treatment of 'Staph' skin infections including folliculitis and small infected cuts or abrasions
Prevention of infection in minor skin trauma
Adjunctive therapy in managing secondary cutaneous bacterial infections
Use in healthcare settings for decolonization protocols to reduce hospital-acquired infections

Side Or Adverse Effects

Local burning, stinging, or pain at the application site
Pruritus (itching) of treated skin
Erythema or redness at the site of application
Contact dermatitis or skin irritation
Uncommon allergic reactions including rash
Rare skin blistering or peeling with extended use
Possible secondary skin infections if bacterial resistance develops
Systemic side effects are rare due to minimal absorption but may include hypersensitivity reactions

Precautions

Avoid application to large areas of damaged or broken skin to prevent systemic absorption
Do not use with occlusive dressings that may increase absorption
Use caution in patients with renal impairment though systemic absorption is low
Avoid use in infants younger than 2 months for ointment and under 3 months for cream unless directed by a physician
Do not use in eyes, nose, mouth, or lips; if contact occurs, rinse thoroughly with water
Do not use concurrently with other topical antibiotics unless prescribed
Monitor for signs of local hypersensitivity or superinfection during prolonged therapy
Pregnancy and breastfeeding safety has not been clearly established; use only if benefits outweigh risks

Warnings

Complete full prescribed course to prevent development of resistant bacteria
Discontinue use and seek medical attention if severe skin irritation, blistering, or allergic reactions occur
Avoid contact with eyes, nose, and mouth; rinse immediately if accidental contact occurs
Avoid spreading to large skin surfaces to prevent systemic exposure
Watch for signs of worsening infection or lack of improvement within 3 to 5 days
Use of topical antibiotics can lead to Clostridioides difficile-associated diarrhea, though rare with mupirocin
Not for oral administration; ingestion can be harmful
Avoid use in pediatric patients younger than the recommended age without medical advice

Contraindications

Known allergy or hypersensitivity to mupirocin or any component of the formulation
Use of mupirocin ointment or cream on deep puncture wounds, burns, or extensive skin lesions without medical supervision
Not indicated for systemic infections or use in oral or ophthalmic infections
Avoid use in patients with a history of severe dermatologic reactions to topical antibiotics

Drug Interactions

Minimal systemic absorption renders significant drug interactions unlikely
Caution advised when using other topical antimicrobial agents concurrently as these may alter efficacy
No known interactions with systemic medications
Avoid concurrent use with other topical medications on the same site unless directed by a physician
Interaction with systemic antibiotics is rare and not clinically significant

Preparations Of The Drug

Topical ointment: Mupirocin calcium 2% ointment for cutaneous application
Topical cream: Mupirocin 2% cream formulation for skin infections
Nasal ointment: Mupirocin nasal 2% ointment for eradication of nasal carriage of S. aureus
Available in tubes of various sizes for outpatient use
Commercial brand names include Bactroban, Centany, Centany AT
Different formulations intended specifically for skin or nasal use to maximize efficacy and safety